Pediatric Crohn's disease is a chronic auto inflammatory bowel disorder affecting children under the age of 17 years. A putative etiopathogenesis of Crohn's disease (CD) is associated with disregulation of immune response to antigens commonly present in the gut microenvironment. Heat shock proteins (HSP) have been identified as ubiquitous antigens with the ability to modulate inflammatory responses associated with several autoimmune diseases. The present study tested the contribution of immune responses to HSP in the amplification of autoimmune inflammation in chronically inflamed mucosa of pediatric CD patients. Colonic biopsies obtained from normal and CD mucosa were stimulated with pairs of Pan HLA-DR binder HSP60-derived peptides (human/bacterial homologues). The modulation of RNA and protein levels of induced proinflammatory cytokines were measured. We identified two epitopes capable of sustaining proinflammatory responses, specifically TNF< and IFN induction, in the inflamed intestinal mucosa in CD patients. The responses correlated positively with clinical and histological measurements of disease activity, thus suggesting a contribution of immune responses to HSP in pediatric CD site-specific mucosal inflammation.
Pediatric Crohn's disease is a chronic auto inflammatory bowel disorder affecting children under the age of 17 years. A putative etiopathogenesis of Crohn's disease (CD) is associated with disregulation of immune response to antigens commonly present in the gut microenvironment. Heat shock proteins (HSP) have been identified as ubiquitous antigens with the ability to modulate inflammatory responses associated with several autoimmune diseases. The present study tested the contribution of immune responses to HSP in the amplification of autoimmune inflammation in chronically inflamed mucosa of pediatric CDpatients. Colonic biopsies obtained from normal and CD mucosa were stimulated with pairs of Pan HLA-DR binder HSP60-derived peptides (human/bacterial homologues). The modulation of RNA and protein levels of induced proinflammatory cytokines were measured. We identified two epitopes capable of sustaining proinflammatory responses, specifically TNF< and IFN induction, in the inflamed intestinal mucosa in CDpatients. The responses correlated positively with clinical and histological measurements of disease activity, thus suggesting a contribution of immune responses to HSP in pediatric CD site-specific mucosal inflammation.
Crohn's disease (CD) is a form of chronic auto-inflammatory bowel disease (IBD) characterized by patchy involvement of the intestinal tract. Although CD can involve any part of the intestine, ileo-colonic involvement is most common [1], [2]. Approximately 20–30 percent of all CDpatients are children. Childhood presentation and subsequent treatment of CD may dramatically impact the patient's growth, development and overall quality of life [1], [3]. CD is pathogenetically based on prolonged remitting/relapsing inflammation of immune origin, which generates damage at local mucosal sites and includes systemic involvement. Immunological, genetic and environmental factors could stochastically overlap in triggering and perpetuating the inflammatory processes [4]. This study addresses the hypothesis that local inflammation is the outcome of inappropriate immune responses to common environmental stimuli, and that such responses contribute to disease activity independently of the events that have triggered the disease [2], [4], [5]. Such antigens should be available within both the microbial flora and the target tissue, over-expressed at the site of inflammation [6], [7] and strongly antigenic [8], [9], [10]. A growing body of work [8], [11]–[14], including our own published findings [15]–[17], implicate that heat shock proteins (HSP) are among the antigens capable of sustaining such immune/autoimmune inflammation.We have demonstrated in various autoimmune diseases that HSP-derived epitopes are capable of inducing and modulating specific T-cell responses and that such modulation correlates with disease activity [15], [18], [19]. CD constitutes an ideal disease model to test this hypothesis, as it often presents with patchy intestinal involvement [1], [3], enabling us to compare inflamed and non-inflamed areas within the same individual, at the same time point. In the present study, we tested three pediatric populations - CD, Ulcerative Colitis (UC) and normal healthy patient biopsies.These patient groups were tested for immune responses to a pool of HSP-derived peptides designed to be Pan HLA-DR binders (in order to overcome variability in presentation due to MHC polymorphisms). These peptides were engineered to be T-cell epitopes to focus on T-cell-mediated responses. Mucosal biopsies from inflamed and non-inflamed areas (as well as control patients without CD) were obtained and probed for production of cytokines involved in modulation of the immune response. Immunological data were correlated with clinical and histological data pertaining to disease activity.
Results
HSP60/65 peptide selection
The selection of the HSP60/65-derived peptide was performed using a mathematical algorithm as described in Sette et al. [20]. A list of peptides predicted to be good Pan-DR binders was generated. Affinity to 15 different HLA types was tested in binding assays for four human/bacterial homologous peptide pairs, including the ones described here [19]. Preliminary studies showed that the pairs P1–P2 and P7–P8 (see Table 1) were the most antigenic of the pool for pediatric CDpatients (not shown).
Table 1
HPS60/65-derived peptides included in the study.
Name
Species
Accession N°
aa position
aa sequence
P1
mycobacterium tuberculosis
CAA17397.1
254–268
GEALSTLVVNKIRGT
P2
Homo sapiens
AAH02676.1
280–294
GEALSTLVLNRLKVG
P7
mycobacterium tuberculosis
CAA17397.1
507–521
IAGLFLTTEAVVADK
P8
Homo sapiens
AAH02676.1
535–549
VASLLTTAEVVVTEI
Pan-DR binding motives are highlighted in bold underlined or bold italics when more than one Pan-DR-binding site is present. P1-P8 refers to the name give to the chosen peptides, aa: amino-acid.
Pan-DR binding motives are highlighted in bold underlined or bold italics when more than one Pan-DR-binding site is present. P1-P8 refers to the name give to the chosen peptides, aa: amino-acid.
Proinflammatory reactivity to HSP-derived peptides is found in inflamed but not in normal mucosa in CD patients, UC patients or healthy patients
Proinflammatory reactivity to P2 and P7 peptides is characteristically disease- and site-specific
Peripheral blood mononuclear cells (PBMC) from the CDpatients tested with the HSP-derived peptides had the same responses as normal controls (not shown). A comparison of patients with ulcerative colitis (UC) disease or healthy controls showed no differences in the induction of proinflammatory cytokines in response to stimulation with P2 and P7. However, the UC patient group showed reactivity to a different group of HSP-derived peptides (not shown). Disease-specific recognition patterns for HSP-derived T-cell epitopes is a phenomenon we have described in several autoimmune diseases and was confirmed here [12], [15]–[17].
Correlation of immunological response between homolog peptide pairs
Correlation of proinflammatory cytokine response between HSP60/65-derived homolog pairs.
Logarithmic values of QRT-PCR results of each HSP60-derived pair were correlated using Pearson correlation, n = 13 and a 95% confidence interval. Circles enclosing data points are shown to indicate the patient excluded, in secondary analysis, to demonstrate that correlations are not due to outliers.
Correlation of proinflammatory cytokine response between HSP60/65-derived homolog pairs.
Logarithmic values of QRT-PCR results of each HSP60-derived pair were correlated using Pearson correlation, n = 13 and a 95% confidence interval. Circles enclosing data points are shown to indicate the patient excluded, in secondary analysis, to demonstrate that correlations are not due to outliers.
Immune response to HSP60/65-derived peptide in inflamed colonic mucosa are skewed toward an inflammatory rather than a regulatory phenotype
The expression pattern of IL4, IL10 and TGF® mRNA levels was analyzed following peptide-specific stimulation. None of the peptides included in the study were able to induce statistically significant differences in the expression level of IL4, IL10 and TGF® when cytokines were analyzed individually. IL10 induction between CDpatients versus controls showed no statistically significant differences between the groups, with P-values of 0.6767; 0.3891; 0.2718 and 0.9829 for P1, P2, P7 and P8, respectively. Similarly, no statistical difference was found between control and CD for the TGF® and IL4 induction (not shown).The ratio between IL10 and TNF〈 resulting from HSP60-derived peptides stimulation was determined to quantitatively assess the balance between regulatory and inflammatory functions in the intestinal mucosa of normal individuals versus CDpatients. Interestingly, the IL10/TNF〈 ratio between normal control and CD groups were statistically significantly different for HSP60-derived peptide stimulation with P1, P7 and P8. The P-values obtained by comparison of the study populations were 0.0137, 0.0162 and 0.0406 for P1, P7 and P8, respectively. Conversely, no statistically significant difference was found for P2, perhaps due to the size of the standard deviation in the control group (Table 2).
Table 2
IL10 to TNF〈 ratio deduced from epitope-specific cytokine production of biopsies of control and CD patients.
IL10/TNFα ratio
Peptide
Control (n = 11)
CD (n = 12)
P-value
P1
1.29 (1.26)
0.95 (0.95)
*0.0137
P2
1.12 (17.68)
0.99 (0.76)
0.2345
P7
1.39 (2.07)
0.97 (1.26)
*0.0162
P8
1.19 (2.19)
0.93 (0.50)
*0.0406
Ratios are expressed as median (range) and P-values calculated by unpaired t-test analysis between groups. Positive significant correlation is shown with *.
Ratios are expressed as median (range) and P-values calculated by unpaired t-test analysis between groups. Positive significant correlation is shown with *.
Immunological proinflammatory responses to HSP-peptides correlate with disease activity
IFNγ and TNFα are CD4 positive producing T cells in the biopsies of inflamed CD mucosa
To validate the QRT-PCR data and to assess the contribution of T cells to the local inflammatory process, immunohistochemistry was performed (Figure 5). Analysis of inflamed and normal biopsies indicated that IFNγ and TNFα producing cells were CD4 positive T cells with an increased amount of colocalization found in inflamed tissue from patients with CD. In addition, inflamed biopsies showed upregulation of IL23 and an abundance of HSP60 expression in CD4 positive T cells. Only inflamed tissue expressed IL17. IL-10 and FoxP3 expression was not detected in the biopsies (data not shown).
Figure 5
CD4 T cells produce TNFα, IFNγ, IL23 and HSP 60.
Immunohistochemical analysis of inflamed CD sections shows the colocalization of TNFα, IFNγ, IL23 and HSP60 with CD4. CD4 FITC (shown in green) and TNF〈, IFNγ, IL23, or HSP60 (shown in red) can be detected in inflamed sections. Additionally, IL-17 (shown in green) producing cells can be seen in inflamed sections. White arrows depict a representative double labeled cell and red arrows depict a representative single labeled cell.
CD4 T cells produce TNFα, IFNγ, IL23 and HSP 60.
Immunohistochemical analysis of inflamed CD sections shows the colocalization of TNFα, IFNγ, IL23 and HSP60 with CD4. CD4FITC (shown in green) and TNF〈, IFNγ, IL23, or HSP60 (shown in red) can be detected in inflamed sections. Additionally, IL-17 (shown in green) producing cells can be seen in inflamed sections. White arrows depict a representative double labeled cell and red arrows depict a representative single labeled cell.
Patients were recruited from the pediatric gastroenterology outpatient and inpatient services at Children's Hospital, San Diego. Healthy patients and IBD patients undergoing colonoscopy for varying routine indications were asked to participate in this study. The Human Research Protection Programs of University of California San Diego and Children's Hospital of San Diego approved consent forms were completed for each enrolled subject. IBD Study Group: Inclusion criteria were children between 3–17 years of age, with IBD undergoing colonoscopy as part of their initial or follow-up evaluation. Exclusion criteria were the evidence of concurrent gastrointestinal infection, allergic colitis or any other chronic disease involving the intestinal tract. Healthy Control Group: Inclusion criteria were children undergoing colonoscopy for specific gastrointestinal symptoms, but who were found to have normal endoscopy and histology, anal fissures or single juvenile polyp.
Study Subjects
No significant differences in age, gender or ethnicity were detected in the patient population used. The study population was composed as follows: 11 subjects in the healthy patient control, 13 in the CD and 13 in the UC group.
Clinical Procedure
All procedures were performed under general anesthesia by a pediatric gastroenterologist. Biopsies were taken through the Olympus PCF100 colonoscope (Melville, NY) using disposable multiple sample biopsy forceps (Boston Scientific, Watertown, MA).
Disease activity index and Histology
In patients with CD, clinical disease activity was evaluated using the Pediatric Crohn's Disease Activity Index (PCDAI) [22] at enrollment. For histological examination, colon biopsies were fixed using standard processing on formalin-fixed paraffin embedded tissue. Biopsy sections were stained with Hematoxylin 2 and Eosin Y (Richard-Allan Scientific Kalamazoo, MI), according to manufacturer's instructions. Analyzed tissues were scored for the degree of inflammation as follows: Acute inflammation (0 normal, 1 mild, 2 moderate and 3 severe); Chronic inflammation (0 normal, 1 mild, 2 moderate and 3 severe); Ulceration (0 present and 1 absent); and Crypt abscesses (0 present and 1 absent). The maximum histology score was 8. The pathologist was blinded to patient's clinical history.
Peptide selection
All HSP60/65-derived peptides were designed using a computing algorithm developed by Dr. Sette (LIAI, La Jolla, CA) [20] and validated by using HLA-DR in binding assays [19]. All peptides used in this study were HSP60/65-derived peptides (Synthetic Biomolecules Inc., San Diego, CA) of 15 amino acid length originated from the conserved regions of human and Mycobacterium tuberculosisHSP60/65. Due to limitations of biopsy sample size, only two sets of peptides were chosen for this study and are shown in Table 1. Additionally, the P1/P2 and P7/P8 homolog pairs were chosen due to their optimum Pan DR scores in the microbial and human epitopes, respectively [19].
Biopsy stimulation
The operator, blinded to clinical and histological reports, performed the peptide stimulation of biopsy sample in addition to immunological analysis. Whenever possible, two sets of biopsies per patient were obtained from endoscopically normal and abnormal colonic mucosa at gross appearance. Biopsies were washed once in fresh media; cultured directly in U-bottom 96-well plate in a final volume of 200 l for 36 hours in complete media (RPMI 1640, 10% heat-inactivated serum, Penicillin, streptomycin, and L-Glutamine) in a 5% CO2 incubator at 37°C. Incubation with HSP60/65-derived peptides was done at 10 µg/ml or with phytohemagglutinin (PHA) at 2.5 µg/ml. Samples were disrupted by adding Lysis buffer and frozen at −80°C up to 1 month before RNA extraction.
Quantitative Real Time PCR assessment of cytokine expression
Statistical analysis was performed using GraphPad Prism (GraphPad Software, San Diego CA). When necessary, a log transformation was performed to obtain a normal distribution. Parametric t-test was used for between-groups comparisons. In all cases, log transformation was used at a confidence interval of 95%. A P value of <0.05 was considered significant. Two-tailed evaluation was always applied for the statistical tests. Pearson correlation coefficients were calculated to assess relationships between Induction Index and PCDAI or Histologic score or in between peptides.
Authors: George Füst; Katalin Uray; László Bene; Ferenc Hudecz; István Karádi; Zoltán Prohászka Journal: Cell Stress Chaperones Date: 2011-10-29 Impact factor: 3.667
Authors: Maurizio Bellavia; Giovanni Tomasello; Marcello Romeo; Provvidenza Damiani; Attilio I Lo Monte; Luciano Lozio; Claudia Campanella; Antonella Marino Gammazza; Francesca Rappa; Giovanni Zummo; Massimo Cocchi; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello Journal: Med Microbiol Immunol Date: 2013-07-18 Impact factor: 3.402
Authors: M Arvonen; P Vähäsalo; S Turunen; H M Salo; M Mäki; K Laurila; O Vaarala; T J Karttunen Journal: Clin Exp Immunol Date: 2012-12 Impact factor: 4.330
Authors: Ana Cristina Gomes-Santos; Rafael Pires de Oliveira; Thaís Garcias Moreira; Archimedes Barbosa Castro-Junior; Bernardo Coelho Horta; Luísa Lemos; Leonardo Augusto de Almeida; Rafael Machado Rezende; Denise Carmona Cara; Sérgio Costa Oliveira; Vasco Ariston Carvalho Azevedo; Anderson Miyoshi; Ana Maria Caetano Faria Journal: Front Immunol Date: 2017-01-30 Impact factor: 7.561